# US 2025/0082659 A1 · Manno-oligosaccharide compositions for pathogen control

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082659 A1
- Document ID: US20250082659A1
- Status: Published application
- Kind: A1
- Application number: 18/569,494
- Filed: 2023-08-15
- Published: 2025-03-13
- Earliest claimed: 2022-08-15
- Assignees: Greensage Prebiotics Inc.
- Applicants: Greensage Prebiotics Inc.
- Inventors: Bradley Arthur SAVILLE
- Web page: https://patentgrep.com/patent/US20250082659A1

## CPC

- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A23L 33/125: containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates (indigestible substances A23L33/21)
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 31/546: containing further heterocyclic rings, e.g. cephalothin
- A61K 31/65: Tetracyclines
- A61K 31/7004: Monosaccharides having only carbon, hydrogen and oxygen atoms
- A61K 31/7036: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 31/716: Glucans
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/04: Antibacterial agents
- C08L 5/00: Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

The present application includes a composition comprising manno-oligosaccharide (MOS) carbohydrates for use in inhibiting growth of pathogenic bacteria and/or promoting growth of beneficial bacteria in a subject, wherein at least 70% wt of the MOS carbohydrates are mannose sub-units. The MOS is derived from mannan material provided from plant sources. The composition has a low average DP which provides improved solubility of the composition. The present application also includes a method of preparing the composition.

## Claims

### Claim at position 1

1-35. (canceled)

### Claim 36

A combination of manno-oligosaccharide (MOS) carbohydrates composition and an antibiotic, wherein the efficacy of the antibiotic is increased by at least 30%.

### Claim 37

(canceled)

### Claim 38 (depends on 36)

The combination of claim 36, wherein at least 85% wt of the MOS carbohydrates are mannose sub-units.

### Claim 39 (depends on 36)

The combination of claim 36, wherein the MOS is derived from mannan material provided from plant sources selected from palm kernel cake, coconut residue, softwoods such as pine or spruce, residuals from coffee processing, acai seeds and residues, and copra meal.

### Claim 40

(canceled)

### Claim 41 (depends on 36)

The combination of claim 36, wherein the antibiotics is selected from penicillin, amoxicilin, gentamycin, clindamycin, kanamycin, tetracycline, erythromycin, ciprofloxacin, vancomycin and ceftazidime.

### Claim at position 8

42-43. (canceled)

### Claim 44 (depends on 36)

The combination of claim 36, wherein the pathogenic bacteria is selected from the group consisting from species of Vibrio, Tenacibaculum, Clostridia, Salmonella, Streptococcus, Aeromonas, Campylobacter, Bacillus, Klebsiella, Listeria, Shigella, Escherichia coli and Piscirickettsia salmonis or pathogenic bacteria containing Type I fimbriae.

### Claim at position 10

45-74. (canceled)

### Claim 75

A method of inhibiting growth of pathogenic bacteria and/or promoting growth of beneficial bacteria in a subject, comprising administering to the subject a composition comprising manno-oligosaccharide (MOS) carbohydrates wherein at least 70% of the MOS carbohydrates are mannose sub-units.

### Claim 76 (depends on 75)

The method according to claim 75, wherein the MOS is derived from mannan material provided from plant sources selected from palm kernel cake, coconut residue, softwoods such as pine or spruce, residuals from coffee processing, acai seeds and residues, and copra meal.

### Claim 77 (depends on 75)

The method according to claim 75, wherein the DP is from 2 to 10.

### Claim 78 (depends on 77)

The method according to claim 77, wherein the MOS having DP of 2 is present in the composition at a content of over 50 wt %.

### Claim 79 (depends on 75)

The method according to claim 75, wherein at least 85% wt of the MOS carbohydrates are mannose sub-units.

### Claim 80 (depends on 75)

The method according to claim 75, wherein the composition has a water solubility of above 90% at 15 wt % to 25 wt % aqueous solution of the composition at 25° C.

### Claim 81 (depends on 80)

The method according to claim 80, wherein the composition has a water solubility of about 100% at 15 wt % to 25 wt % aqueous solution of the composition at 25° C.

### Claim 82 (depends on 75)

The method according to claim 75, wherein the mannose sub-units comprise predominantly b-1,4 linkages.

### Claim 83 (depends on 75)

The method according to claim 75, wherein the composition has a total glucose and galactose content of less than 10% wt of the MOS.

### Claim 84 (depends on 75)

The method according to claim 75, wherein the composition is free from fructose.

### Claim 85 (depends on 75)

The method according to claim 75, wherein the composition further comprises b-glucan, wherein the content of the b-glucan is from about 0.5% wt to about 5% wt of the MOS.

### Claim 86 (depends on 75)

The method according to claim 75, wherein the composition further comprises an agent selected from the group consisting of probiotics, prebiotics, polyphenols, phages, clays and minerals such as bentonite and montmorillonite, antibiotics and short chain fatty acids.

### Claim 87 (depends on 75)

The method according to claim 75, wherein the pathogenic bacteria is selected from the group consisting of species of Vibrio, Tenacibaculum, Clostridia, Salmonella, Streptococcus, Staphylococcus, Aeromonas, Campylobacter, Bacillus, Klebsiella, Listeria, Shigella, Escherichia coli and Piscirickettsia salmonis, or pathogenic bacteria containing Type I fimbriae.

### Claim 88 (depends on 87)

The method according to claim 87, wherein the growth of the pathogenic bacteria is inhibited by at least 20%.

### Claim 89 (depends on 75)

The method according to claim 75, wherein the composition further comprises antibiotics.

### Claim 90 (depends on 89)

The method according to claim 89, wherein the MOS increases the efficacy of the antibiotics.

### Claim 91 (depends on 89)

The method according to claim 89, wherein the antibiotic is selected from penicillin, amoxicilin, gentamycin, clindamycin, kanamycin, tetracycline, erythromycin, ciprofloxacin, vancomycin and ceftazidime.

### Claim 92 (depends on 75)

The method according to claim 75, wherein the growth of Clostridium perfringens is inhibited by at least 20%, wherein the growth of Salmonella enteritidis is inhibited by at least 20%, the growth of Tenacibaculum maritimum is inhibited by at least 20%, the growth of Vibrio parahaemolyticus is inhibited by at least 20%, the growth of Vibrio aguillarum is inhibited by at least 20%, the growth of Vibrio harveyi is inhibited by at least 20%, the growth of Piscirickettsia salmonis is inhibited by at least 20%, the growth of Streptococcus mutans is inhibited by at least 20%, the growth of Escherichia coli is inhibited by at least 20% or the growth of Listeria monocytogenes is inhibited by at least 20%.

### Claim 93 (depends on 75)

The method according to claim 75, wherein the composition is administered to the subject as a supplement, food, beverage or feedstock.

### Claim 94 (depends on 75)

The method according to claim 75, wherein the composition is administered to the subject as a capsule, tablet, sachet or liquid.

### Claim 95 (depends on 75)

The method according to claim 75, wherein the composition is administered to the subject as a vaccine adjuvant.
